Market Newsdesk

FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, President and Chief Executive Officer, will make a corporate presentation at the LifeSci Partners 10^th Annual Healthcare Corporate Access Event, on Thursday, January 7, 2021 at 11am Eastern Time.

Anticipating the launch in 1Q21 of a Phase 2 trial evaluating Nyxol^® and low-dose pilocarpine eye drops to treat presbyopia, Ocuphire will also be joining a panel with other companies engaged in developing eye drops as an alternative to reading glasses. The panel, Discussion on New Advances for Presbyopia, is scheduled for Friday, January 8^th at 12pm Eastern Time.

Investors interested can pre-register for both the corporate presentation and Discussion on New Advances for Presbyopia panel here. The corporate presentation will include Ocuphire’s accomplishments in 2020 and plans for 2021 including upcoming data readouts for Phase 2 and 3 trials. The format for both events will be a virtual presentation with the opportunity for Q&A at the conclusion.

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol^® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal pharmacologically-induced mydriasis (RM), and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s ongoing and upcoming trials. For more information, please visit www.ocuphire.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates and potential. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, and (vii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
  
Ocuphire Contacts

Mina Sooch, President & CEO 
Ocuphire Pharma, Inc. 
[email protected]
www.ocuphire.com 

Corey Davis, Ph.D.
LifeSci Advisors
[email protected]

HERZLIYA, Israel, Dec. 30, 2020 (GLOBE NEWSWIRE) — Safe-T® Group Ltd. (NASDAQ, TASE: SFET), a provider of secure access solutions for on-premise and hybrid cloud environments, has been recognized as a Representative Vendor in Gartner’s December 2020 report titled, “SASE Will Improve Your Distributed Security Everywhere.”¹

________________

1 Gartner, Inc. ” SASE Will Improve Your Distributed Security Everywhere ” by Richard Bartley, December 8, 2020.

This recognition from Gartner, the world’s leading research and advisory company, follows a June 2020 announcement, in which Safe-T was  named a Representative Vendor of Stand-Alone ZTNA.

Secure Access Service Edge (SASE) is a new enterprise networking technology category introduced by Gartner in the August 2019 report “The Future of Network Security in the Cloud“. SASE converges the functions of network and security point solutions into a unified, global cloud-native service. It is an architectural transformation of enterprise networking and security that enables information technology (IT) to provide a holistic, agile and adaptable service to the digital business. What makes SASE unique is its transformational impact across multiple IT domains converging of wide area networking (WAN) and network security services into a single, cloud-delivered service model, allowing organizations to shift towards a more dynamic and adaptive network.

According to Gartner, “SASE is as an emerging architecture combining comprehensive WAN capabilities with comprehensive network security functions (such as SWG, CASB, FWaaS and ZTNA) to support the dynamic secure access needs of digital enterprises. ZTNA is a capability that — irrespective of whether it operates as an endpoint or service-initiated model, or whether it is deployed as a stand-alone appliance or is consumed as a service — is always ingress SASE. It provides strictly controlled access to internal systems and applications.”

Safe-T ZoneZero

™ is the leading ZTNA solution in the market today, and it is the only ZTNA solution that unifies all access use cases, supporting VPN users, non-VPN users and internal users alike. With ZoneZero™, organizations can support all access scenarios:

• All user types – people (managed or unmanaged), applications, APIs and connected devices
• All user locations – external or internal
• All application types – new or legacy
• All application locations – cloud or on-premises

Safe-T’s ZoneZero™ offers secure, transparent and controlled access for all types of entities—whether they are people, applications or connected devices—to any internal application, service, and data (HTTP/S, SMTP, SFTP, SSH, APIs, RDP, SMB, thick applications, etc.). By leveraging Safe-T’s patented reverse-access (outbound) technology, ZoneZero™ can eliminate the need to open incoming ports in the corporate firewall.

Gartner also stated, “Replacing or extending client VPN with ZTNA services for remote access to applications. Expand the use of ZTNA so it performs more than just “TLS VPN”; use its software-defined perimeter capabilities. Take advantage of any techniques to reduce attack surface, such as using single-packet authorization.”

Gartner Disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s Research & Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Safe-T®

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of access solutions which mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Safe-T’s cloud and on-premises solutions ensure that an organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of zero trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.

Safe-T’s wide range of access solutions reduce organizations’ attack surface and improve their ability to defend against modern cyberthreats. As an additional layer of security, our integrated business-grade global proxy solution cloud service enables smooth and efficient traffic flow, interruption-free service, unlimited concurrent connections, instant scaling and simple integration with our services. With Safe-T’s patented reverse-access technology and proprietary routing technology, organizations of all size and type can secure their data, services and networks against internal and external threats. At Safe-T, we empower enterprises to safely migrate to the cloud and enable digital transformation.

For more information about Safe-T, visit www.safe-t.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses the potential benefits of its products and the leading position in the market of its ZoneZero™ solution. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

INVESTOR RELATIONS CONTACT

Gary Guyton
MZ Group – MZ North America
469-778-7844
[email protected]
www.mzgroup.us

Michal Efraty
+972-(0)52-3044404
[email protected]

PRESS CONTACT

Maya Meiri
[email protected]
+972-9-8666110

 

CHICAGO, Dec. 30, 2020 (GLOBE NEWSWIRE) — GATX Corporation (NYSE:GATX) today announced its acquisition of Trifleet Leasing Holding B.V., the fourth largest global tank container lessor. Headquartered in the Netherlands with offices worldwide, Trifleet owns and manages a fleet of over 18,000 tank containers leased to a diverse customer base in the chemical, industrial gas, energy, food, cryogenic and pharmaceutical industries, as well as to tank container operators.

“Trifleet complements our existing railcar leasing business and shares GATX’s approach of striving for the highest levels of safety, quality, customer service and environmentally responsible performance,” said Brian A. Kenney, president and chief executive officer of GATX. “We are committed to strengthening Trifleet’s position in the tank container leasing market by leveraging GATX’s extensive global customer base and experience in managing long-lived, widely used transportation assets.”

GATX closed its acquisition of Trifleet on Dec. 29, 2020 for approximately €175 million in cash.

COMPANY DESCRIPTION


GATX Corporation (NYSE:GATX) strives to be recognized as the finest railcar leasing company in the world by our customers, our shareholders, our employees and the communities where we operate. As the leading global railcar lessor, GATX has been providing quality railcars and services to its customers for over 121 years. GATX has been headquartered in Chicago, Illinois since its founding in 1898.

AVAILABILITY OF INFORMATION ON GATX’S WEBSITE


Investors and others should note that GATX routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the GATX Investor Relations website. While not all of the information that the Company posts to the GATX Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in GATX to review the information that it shares on www.gatx.com under the “Investor Relations” tab.

FOR FURTHER INFORMATION CONTACT:


GATX Corporation
Shari Hellerman
Director, Investor Relations
GATX Corporation
312-621-4285
[email protected]

DENVER, Dec. 30, 2020 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), is pleased to announce that upon paying US$3,171,540 on December 24, 2020, it has made the final payment in connection with the previously announced acquisition (the “Acquisition”) of all of the assets of Neuro-Pro Monitoring (“Neuro-Pro”). The early payment of the balance of the purchase price resulted in a reduced cost to Assure of US$170,000. Accordingly, the total purchase price paid in connection with the Acquisition was US$7,529,231.

“As anticipated, Neuro-Pro has strengthened and diversified our revenue stream, substantially increased our scale in terms of number of procedures and was immediately accretive to Assure’s earnings and cash flow in 2020,” said John A. Farlinger, Assure’s executive chairman and CEO. “In addition, we further developed important relationships that Neuro-Pro originated with some of the most prestigious spine surgeons in the Dallas Ft. Worth area. These introductions have accelerated our expansion in Texas and drove the initiation of clinical research projects that will highlight the value Assure provides for IONM-related efficacy, safety, cost saving and improving patient outcomes. We believe our enhanced scale and data-driven studies will help accelerate the negotiation of new in-network contracts with insurance companies.”

Farlinger added, “The final terms of the Acquisition were highly favorable from a cost of capital perspective. We are pleased that Assure shareholders have benefited from an immediately accretive transaction as well as from a reduced sale price resulting from our early payment discount.”

Farlinger concluded, “Given current dynamics in the IONM industry, we anticipate opportunities for additional M&A on favorable terms for Assure.”

Jason Papes, Neuro-Pro’s principal said, “With the scale, resources and expertise that Assure provides, we have taken advantage of opportunities to expand in Texas. In addition, the integration process was smooth, and we have benefitted from continuing education and progressive training for our clinical team that aligns with our principles, ensures advanced patient care and supports our future development plans.”

As announced on February 18, 2020, Assure acquired Neuro-Pro, one of the largest IONM companies serving the Dallas Ft. Worth metroplex.

About Assure Holdings

Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. While Assure focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission’s Gold Seal of Approval®. For more information, visit the company’s website at www.assureneuromonitoring.com.

About Neuro-Pro Monitoring

Established in 2012, Neuro-Pro Monitoring is a premier intraoperative neuromonitoring company serving the Dallas Ft. Worth metroplex. Over the past eight years, Neuro-Pro has grown into a distinguished organization focused on patient care, employee satisfaction and customer service. The company’s 13 technologists supporting 25 surgeons across 14 facilities. Neuro-Pro has established a reputation of excellence by the way we conduct ourselves, our business and treating our employees and customers with the highest respect.

Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to: the effect of clinical research projects and the effect of Assure’s scale and data-driven studies; that there will be additional M&A opportunities on favorable terms; and the comments with respect to strategies, expectations, planned operations, and future actions of the Company. Forward-looking statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: growing competition in the IONM industry; the Company’s ability to execute its growth plans; the Company’s ability to continue to make acquisitions in the IONM industry; clinical research projects may not highlight the value Assure provides; the Company’s scale and data-driven studies may not help accelerate the negotiation of new in-network contracts with insurance companies; the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general; that the Company’s actions taken during the COVID-19 health crisis will be effective; and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-287-3093
[email protected]

John Farlinger, Chief Executive Officer
Assure Holdings Corp.
1-604-763-7565
[email protected]

SAN CARLOS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of U.S. Patent No: 10,874, 831 for “Devices and Methods for Accessing the Vasculature of a Patient” that further protects the Helix™ Biotherapeutic Delivery System and enhances its cell therapy delivery capabilities.

This patent covers a steerable design intended to provide uniform bending rigidity in all orientations. This uniform bending rigidity is expected to significant enhance physician control in tortuous anatomy. The patented technology is incorporated in the Company’s recently approved Morph DNA and AVANCE steerable catheter offerings. The advances also are expected to strengthen the Company’s clinical stage biotherapeutic programs in heart failure and chronic myocardial ischemia. 

“We continue to believe that delivery is critically important to successful biotherapeutic treatment. You can have a promising cell therapy, but if sub-par delivery doesn’t facilitate biologic retention by the heart or has a poor safety profile, it can cause a therapy to fail,” said BioCardia CEO Peter Altman, Ph.D. “At BioCardia, we have always recognized the important role delivery plays in the overall success of our therapeutics and in their promise to improve the lives of millions of patients with heart disease. This additional patent protection for technology to enhance physician control for all steerable catheter systems, is anticipated to have value and impact beyond the scope of our biotherapeutic programs, initially through our Avance product offering.”

About BioCardia®

BioCardia, Inc.
, headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company’s products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.

Forward Looking Statements:

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. These forward-looking statements include, without limitation, statements relating to the impact of our catheter technologies on procedural control and safety as well as the likelihood of success and the value of our clinical cell therapy programs.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. These forward-looking statements reflect our view as of the time such statement is made and are not guarantees of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors including, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans and overall market conditions. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate.  Additional factors that could materially affect actual results can be found in our documents filed with the SEC, including our recent filings on Form 8-K, Form 10-K and Form 10-Q, particularly any statements under the caption entitled “Risk Factors” Therein.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

INVESTOR CONTACT:

David McClung, Chief Financial Officer
[email protected]
(650) 226-0120

MEDIA CONTACT:

Michelle McAdam, Chronic Communications, Inc.
[email protected]
(310) 545-6654

 

• Year-over-year growth rates accelerated to over 20% in December (from 10% in the third quarter)
• The Opera GX gaming browser grew to over 7 million gamers in December, up 3.5 times year-over-year

OSLO, Norway, Dec. 30, 2020 (GLOBE NEWSWIRE) — Opera Limited (NASDAQ: OPRA), one of the world’s major browser developers and a leading internet consumer brand, announced today that its PC user base has grown to 80 million monthly active users in December, representing accelerated year-over-year growth in excess of 20%. The strong user gains were driven by Opera GX, the world’s only dedicated gaming browser, which exceeded 7 million gamers in December, an increase of 3.5 times compared to the prior year.

“Opera PC users have nearly doubled since the beginning of 2017 as Opera has focused on providing innovative browsing experiences and differentiated features to users looking for an alternative to system default browsers,” said Krystian Kolondra, EVP of PC and EEA Fintech. “This growth shows that our offerings are resonating, highlighted by record engagement from unique features like built-in communicators, workspaces, and other convenience features. Further, it represents an important contributor to our financial results and bolsters our browser+ strategy, where we leverage our browsers to launch new products including Opera News and our European fintech solutions.”

About Opera

Opera is a global web innovator. Opera’s browsers, news products and fintech solutions are the trusted choice of more than 380 million people worldwide. Opera is headquartered in Oslo, Norway and listed on the NASDAQ stock exchange (OPRA).

Investor Relations Contact:

Derrick Nueman
[email protected] or (408) 596-3055

For media enquiries, please contact: [email protected]

PETAH TIKVA, Israel, Dec. 30, 2020 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that its Board of Directors has declared a cash dividend to shareholders in the amount of $0.63 per share (approximately $35 million in the aggregate) following receipt of court approval for the distribution of the dividend. The dividend will be paid in US$ on January 20, 2021 to shareholders of record on January 11, 2021. Together with the $20M dividend distributed at the beginning of this month, the aggregate amount of dividends payable to shareholders adds up to approximately $55 million, or $0.99 per share. Further, Gilat’s interim CFO, Bosmat Halpern, has been named Gilat’s CFO.

“I am pleased to have obtained the Court approval for the distribution of this meaningful dividend to our shareholders,” said Adi Sfadia, Gilat’s CEO. “After this distribution the Company still has a very meaningful cash position, in addition to its real estate assets, that will allow it to execute on possible opportunities we are exploring,” added Mr. Sfadia.

“I want also to take this opportunity to congratulate Gilat’s interim CFO, Bosmat Halpern, on her appointment as Gilat’s CFO. I am confident in her ability to apply her wealth of experience to navigate Gilat wisely to a successful 2021,” concluded Mr. Sfadia.

The Company will withhold tax in accordance with Israeli tax law. The Company has requested a ruling from the Israel Tax Authority in connection with the dividend and will announce the main terms of the ruling once it is obtained.

About Gilat

Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT) is a leading global provider of satellite-based broadband communications. With 30 years of experience, we design and manufacture cutting-edge ground segment equipment, and provide comprehensive solutions and end-to-end services, powered by our innovative technology. Delivering high value competitive solutions, our portfolio comprises of a cloud based VSAT network platform, high-speed modems, high performance on-the-move antennas and high efficiency, high power Solid State Amplifiers (SSPA) and Block Upconverters (BUC).

Gilat’s comprehensive solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense and public safety, all while meeting the most stringent service level requirements. Gilat controlling shareholders are the FIMI Private Equity Funds. For more information, please visit: www.gilat.com

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of Gilat to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, risks associated with the outbreak and global spread of the coronavirus (COVID-19) pandemic; changes in general economic and business conditions, inability to maintain market acceptance to Gilat’s products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for Gilat’s products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company’s proprietary technology and risks associated with Gilat’s international operations and its location in Israel. For additional information regarding these and other risks and uncertainties associated with Gilat’s business, reference is made to Gilat’s reports filed from time to time with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements for any reason.

Contact:

Gilat Satellite Networks
Doreet Oren, Director Corporate Communications
[email protected]

GK Investor and Public Relations
Ehud Helft, Managing Partner
[email protected]

CHICAGO, Dec. 30, 2020 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (NASDAQ: IPDN), (“PDN” or the “Company”), a developer and operator of online and in-person networks that provide access to networking, training, educational and employment opportunities for diverse individuals, today announced its partnership with Phala Network, an innovative technology company that specializes in confidentiality-preserving and privacy-first blockchain application development.

Blockchain technology is known for its decentralization and irreversible features that guarantee secured transactions over consensus algorithms; however, the biggest pitfall is its lack of confidentiality. Phala Network uses the technology of Trusted Execution Environment (TEE) to create a Privacy Cloud Platform that could process general-purpose computing with Turing-completeness.

PDN being one of the largest diverse networks in the nation, how to improve the efficiency of matching qualified job seekers with employers and reduce the costs and resources for employers to find the right talent has always been its top priority. “We are excited to partner with Phala Network to explore potential integration of substrate-based, confidential smart contract blockchain technology into our PDN network, which could potentially enhance our delivery rate and protect network users’ and clients’ privacy from data-mining,” said Adam He, CEO of PDN.

Professional Diversity Network, Inc.

Professional Diversity Network, Inc. (PDN) is a developer and operator of online and in-person networks that provides access to networking, training, educational and employment opportunities for diverse professionals. Through an online platform and our relationship recruitment affinity groups, we provide our employer clients a means to identify and acquire diverse talent and assist them with their efforts to recruit diverse employees. Our mission is to utilize the collective strength of our affiliate companies, members, partners and unique proprietary platform to be the standard in business diversity recruiting, networking and professional development for women, minorities, veterans, LGBT and disabled persons globally.

For more information about PDN, please visit:

www.prodivnet.com

About Phala Network

Phala is a private computations cloud based company on Trusted Execution Environment and blockchain, which offers generalized compute at public cloud scale, with a property of base-layer privacy. For now, there are already multi applications built on Phala, including Web3 Analytics, a next-generation, cutting-edge data analysis tool that is able to analyze user data and output results without invading personal privacy.

https://phala.network

Forward-Looking Statements

This press release contains information about PDN’s view of its future expectations, plans, and prospects that constitute forward-looking statements. These forward-looking statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts in this announcement are forward-looking statements, including, but not limited to: any projections of earnings, revenue, or other financial items; any statements regarding the adequacy, availability, and sources of capital, any statements of the plans, strategies, and objectives of management for future operations; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. In addition, there is uncertainty about the continuous spread of the COVID-19 virus and the impact it may have on the Company’s operations, the demand for the Company’s products, and global economic activity in general. PDN may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about PDN’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, whether known or unknown, and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “will make,” “will be,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “endeavor to,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks is included in our annual report and other filings with the U.S. Securities and Exchange Commission (the “SEC”). All information provided in this press release is as of the date of this press release, and PDN undertakes no obligation to update any forward-looking statements, except as may be required under applicable law.

Press Contact for IPDN:

For further information, please contact:

Professional Diversity Network, Inc.
Tel: (312) 614-0950
Email: [email protected] 

Source: Professional Diversity Network, Inc.

HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) — Recruiter.com Group, Inc. (OTCQB: RCRT), a leading AI-powered hiring platform with the world’s largest network of recruiters, unveiled a new program to help 100,000 unemployed people get back to work.

To learn more about the program, please visit start.recruiter.com/no-resume.

“The pandemic has accelerated the use of technology in the hiring process for businesses of all sizes,” said Evan Sohn, Chairman, and CEO of Recruiter.com. “Businesses have turned to platforms like Zoom and Skype to substitute for in-person meetings and live interviews. But changes in hiring practices are still leaving many capable workers behind. It’s now time for new video platforms to be introduced earlier in the hiring process to better address the entire workforce.”

“I often ask our team, who aren’t we servicing well? The answer is, what I call, the ‘unresumed,'” said Sohn. “Unresumed represents people who don’t have a resume, let alone a recruiter or a LinkedIn profile, to support them in getting back to work. To level the playing field, we are offering 100,000 free candidate videos for ‘unresumed’ people. This is an excellent opportunity to show how a simple video can help everyone participate in the recovery of the American economy.”

While there has been some robust recovery since unemployment spiked to 14.7 percent in April 2020, not every worker has been able to share equally in that recovery. Workers with less education have been largely underrepresented in job gains. When unemployment rates are broken down by education levels, it becomes clear that highly educated professionals, who hold highly-skilled roles, are doing much better than the rest of the workforce:

• Bachelor’s degree or higher: 4.2 percent
• Some college/associate’s degree: 6.5 percent
• High school diploma: 8.1 percent
• Less than high school: 9.8 percent

(Source: U.S. Bureau of Labor Statistics, October 2020)

In the wake of COVID-19, hiring processes have largely moved online. Highly educated, highly paid workers are nearly twice as likely as less formally educated workers to have access to high-speed internet and the technological tools that allow them to participate in virtual hiring and remote work. If this digital divide isn’t bridged, hundreds of thousands of American workers could be left behind.

Recruiter.com’s candidate videos are two-minute, TikTok-like snapshots that showcase who a candidate is, their qualifications, and their desired employment. Recruiter.com will sponsor 100,000 candidate video resumes and provide its video platform and curation services to employer partners that wish to hire from within this pool of talented candidates. Added Sohn. “We invite employers and organizations serving this community to join us, as together, we can make a real difference for a lot of people. The time is now for everyone who wants a job to get recruited.”

For more information, go to start.recruiter.com/no-resume.

Recruiter.com Group, Inc.

Recruiter.com is disrupting the $120 billion recruiting and staffing industry by combining an AI and Video hiring platform with the world’s largest network of over 27,500 small and independent recruiters. Businesses of all sizes recruit talent faster using the Recruiter.com platform, which is powered by virtual teams of Recruiters On Demand and Video and AI job-matching technology. Visit https://www.recruiter.com.

For investor information, visit https://www.recruiter.com/investors.html.

Please follow social media channels for additional updates:

• LinkedIn Recruiter Network Group: https://www.linkedin.com/groups/42370/
• LinkedIn Company Page: https://www.linkedin.com/company/1240434
• Twitter Company Page: https://twitter.com/recruiterdotcom
• Facebook Company Page: https://www.facebook.com/RecruiterDotCom

Company Contact:

Evan Sohn

Recruiter.com Group, Inc.

Phone: (855) 931-1500

Investor Relations:

Dave Gentry

RedChip Companies, Inc.

Phone: (407) 491-4498

[email protected]

Cautionary Note Regarding Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements primarily on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include continued demand for professional hiring, the accuracy of the Recruiter Index® survey, the impact of the COVID-19 pandemic on the job market and the economy as virus levels are again rising in many states, and the Risk Factors contained within our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2019. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law.